See more news releases in Biotechnology | Health Care & Hospitals | Medical Pharmaceuticals | Pharmaceuticals | FDA Approval

Breckenridge Announces Approval of Methscopolamine Bromide Tablets

BOCA RATON, Fla., Dec. 9, 2011 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announced that the U.S. Food and Drug Administration granted final approval for their Abbreviated New Drug Application (ANDA) for Methscopolamine Bromide Tablets. Methscopolamine Bromide Tablets are AB rated to Pamine®, a prescription medicine that is used as adjunctive therapy for the treatment of peptic ulcers. Pamine® is marketed by Kenwood Therapeutics. The current market is approximately $7M, based on industry sales data. The product will be available to customers in early 2012.

About Breckenridge:
Breckenridge Pharmaceutical, Inc. is a privately-held pharmaceutical marketing, research and development company founded in 1983 that markets a broad range of generic prescription products in many therapeutic categories. The Breckenridge label is recognized by Wholesalers, Distributors, Chains, and Managed Care Accounts, as well as Retail Pharmacies nationwide. The company markets over 70 products in a variety of dosage forms including: Tablets, Capsules, Soft Gel Capsules, Liquids, Suspensions, and Powders. www.bpirx.com

SOURCE Breckenridge Pharmaceutical, Inc.